Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake
Akiva Mintz · NCT07284589
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–120 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Phase 2
- Target enrollment
- 200
- US sites recruiting
- 1
- Study start
- December 11, 2025
- Record last updated
- April 8, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The goal of this clinical trial is to evaluate an investigational ultralow dose positron emission tomography (PET) imaging technique for neuroendocrine tumor detection and monitoring. The main question it aims to answer is:
Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer that binds to a tumor specific protein called somatostatin receptor 2 (SSTR2) and be imaged on a new type of high sensitivity PET scanner for up to 3 hours
Being studied: 68Ga-Dotatate
Conditions: Healthy (Controls); Healthy Volunteers; Neuroendocrine (NE) Tumors
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Age ≥18 years.
- Ability to provide informed consent and comply with study procedures.
- For female participants: Must not be pregnant or breastfeeding; Negative pregnancy test required for women of childbearing potential.
Exclusion Criteria
- Participants who have exceeded NRC regulation for annual radiation exposure from prior research-related scans, including this study (50 millisievert [mSv] total).
- More than four prior enrollments in this study.
- Participants with severe claustrophobia, chronic pain, or musculoskeletal conditions that prevent completion of the PET scan
- Medication \& Prior Treatment Exclusions: SSTR targeted therapies
- Pregnant or breastfeeding individuals (negative pregnancy test required)
- Inability to provide informed consent
- Any condition that, in the investigator's judgment, may compromise participant safety or study integrity.
Recruiting US locations
Nuclear Imaging Institute
Englewood, NJ 07631
Site contact: Barbara Blanchfield · 9732554955 · bblanchfield@nii.org
Study contacts (from the official record)
- Barbara Blanchfield · 9732554955 · bblanchfield@nii.org
- Dianna Willis, PhD · 973-513-7832 · dewillis@nii.org
Similar studies in New Jersey
All healthy volunteers studies in New Jersey →- RecruitingHealthy volunteersPhase 1
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
Arcutis Biotherapeutics, Inc.
- Location
- Fair Lawn, NJ + 6 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1
A Clinical Trial of MK-1406 in Healthy Participants (MK-1406-008)
Merck Sharp & Dohme LLC
- Location
- Marlton, NJ + 5 other US sites
- Eligibility basics
- Ages 18–64
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Jersey City, NJ + 49 other US sites
- Eligibility basics
- Ages 60+
- RecruitingHealthy volunteersPhase 1
Study of Single Doses of HBS-104 in Acutely Sleep-deprived Healthy Participants
Harmony Biosciences Management, Inc.
- Location
- Eatontown, NJ
- Eligibility basics
- Ages 18–55